Actavis Group has launched Letrozole tablets on day one after the patents expired in Austria, Germany, Finland, Ireland, Italy, the Netherlands, Romania, Sweden and the UK.

At the same time, Letrozole was marketed by Actavis in Poland, a patent free market for this product, and will be launched in a number of European markets over the coming months.

Letrozole tablets are indicated for treatment of postmenopausal women with breast cancer. Available in 2.5mg strength in packs of 14 and 28, Letrozole tablets are developed and manufactured by Actavis in Romania.

Letrozole Actavis is the generic equivalent of Novartis‘ Femara® brand. Brand product sales in Europe in 2010 were about EUR403 million (IMS Health data).